|
12/12/16 |
Thermo Fisher Scientific Again Recognized as a Best Place to Work
for LGBT Equality |
|
|
|
|
|
Agilent Technologies Presents Thought Leader Award to
Bioengineering Researcher Rohit Bhargava of University of Illinois Cancer Center |
|
|
|
|
|
New edition of research, the Bayer scientific magazine, published
Big Data meets Life Sciences
|
|
|
|
|
|
Bayer and Versant Ventures Join Forces to Launch Stem Cell
Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
|
|
|
|
|
12/09/16 |
Novartis LEE011 (ribociclib) plus letrozole analyses show
superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced
breast cancer versus letrozole |
|
|
|
|
12/08/16 |
Bruker MassSpectator, Issue 75, December 2016 |
|
|
|
|
|
Thermo Fisher Scientific Launches Center of Excellence in
Immunotherapy Program |
|
|
|
|
|
Gilead Submits New Drug Application to U.S. Food and Drug
Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir
|
|
|
|
|
12/07/16 |
Bayer strengthens U.S. animal health portfolio:
Boehringer Ingelheim Vetmedica, Inc. and Bayer Enter Into
Agreement for Purchase of U.S. Cydectin® Product Portfolio |
|
|
|
|
12/06/16 |
FDA Approves Genentechs Avastin (Bevacizumab) Plus Chemotherapy
for a Specific Type of Advanced Ovarian Cancer |
|
|
|
|
12/05/16 |
Pfizer and Avillion Announce Positive Top-Line Results for Phase
3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome
Positive Chronic Myeloid Leukemia |
|
|
|
|
12/04/16 |
Incyte:
Pooled Analysis of Five-Year Data from Two Phase 3 Studies
Further Supports Overall Survival Advantage Observed in Patients with
Myelofibrosis Treated With Jakafi (ruxolitinib)
|
|
|
|
|
|
Genentech’s Gazyva Helped People With Previously Untreated
Follicular Lymphoma Live Significantly Longer without their Disease Worsening
Compared to Rituxan |
|
|
|
|
12/03/16 |
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA
Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing
Cutaneous T-Cell Lymphoma |
|
|
|
|
12/02/16 |
Bruker Announces Corporate Partnership with International Phenome
Centre Network (IPCN) for NMR Technologies and SOPs
|
|
|
|
|
|
Amgen And Allergan Submit Biosimilar Marketing Authorization
Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To
Bevacizuma |
|
|
|
|
|
Amgen Announces Launch Of Blood Counts™ And Collaboration With
StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma |
|
|
|
|
12/01/16 |
Thermo Fisher Scientific CRISPR-Cas9 Genome Editing Tools Named
Top Innovations of 2016 |
|
|
|
|
|
LYRICA (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets
Primary Endpoint |
|
|
|
|
09/07/16 |
Bruker Signs Agreement to Acquire Oncovisions Preclinical PET
Imaging Business |
|
|
|
|
|
Thermo Fisher Scientific Prices Offering of Euro-Denominated
Senior Notes |
|
|
|
|
|
Pfizer Appoints Chief Scientific Officer for Neuroscience
Research |
|
|
|
|
|
FDA Accepts Supplemental Biologics License Application, Assigns
Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA®
(pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small
Cell Lung Cancer |
|
|
|
|
09/06/16 |
Sangamo BioSciences Receives Orphan Drug Designation From The FDA
For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing |
|
|
|
|
09/05/16 |
‘Real world’ data shows 83 percent effectiveness for Bexsero® in
infants in first year of UK national meningitis B immunisation programme |
|
|
|
|
09/01/16 |
Amgen
FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric
Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell
Precursor Acute Lymphoblastic Leukemia |
|
|
|
|
|
Amgen
Amgen Obtains Global Development And Commercial Rights From
Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple
Myeloma |
|
|
|
|
|
Bruker MassSpectator, Issue 72, September 2016 |
|
|
|
|
|
Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab)
helped people with a specific type of lung cancer live significantly longer
compared to chemotherapy |
|
|
|
|
09/29/16 |
Novartis drug Afinitor® recommended by CHMP for European Union
approval to treat select GI and lung neuroendocrine tumors |
|
|
|
|
|
European CHMP Adopts Positive Opinion for Gilead’s TAF-Based
Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir
Alafenamide) for Treatment of HIV |
|
|
|
|
04/28/16 |
Christina Applegate and Merck Urge Insomnia Sufferers to Learn
“Why They’re So Awake” |
|
|
|
|
04/27/16 |
Takeda
Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO
(ixazomib) Published in The New England Journal of Medicine |
|
|
|
|
04/25/16 |
Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough
Therapy Designation from U.S. Food and Drug Administration for Previously
Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
|
|
|
|
04/18/16 |
Agilent Technologies Introduces First Commercial Software for
Metabolic Flux Analysis |
|
|
|
|
04/15/16 |
Gilead Announces Full 48-Week Results From Two Phase 3 Studies
Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B
Infection |
|
|
|
|
04/14/16 |
U.S. Food and Drug Administration Accepts for Priority Review
Bristol-Myers Squibb’s Supplemental Biologics License Application for Opdivo® (nivolumab)
for the Treatment of Classical Hodgkin Lymphoma Patients |
|
|
|
|
04/11/16 |
Genentech Announces FDA Grants Venclexta™ (Venetoclax)
Accelerated Approval for People with a Hard-To-Treat Type of Chronic Lymphocytic
Leukemia |
|
|
|
|
04/10/16 |
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy
Atezolizumab in Specific Type of Lung Cancer |
|
|
|
|
04/06/16 |
European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab)
for Previously Treated Advanced Renal Cell Carcinoma |
|
|
|
|
04/04/16 |
U.S. Food and Drug Administration Approves Descovy® (Emtricitabine,
Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy |
|
|
|
|
|
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’
Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases |
|
|
|
|
04/01/16 |
Bristol-Myers Squibb Completes Previously Announced Acquisition
of Padlock Therapeutics, Inc. |
|
|
|
|
|
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab)
in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma |
|
|
|
|
03/24/16 |
Appeals Court Upholds Depomed Patents Asserted against Purdue
Pharma |
|
|
|
|
03/14/16 |
FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority
Review for Advanced Bladder Cancer |
|
|
|
|
03/07/16 |
Merck:
FDA Accepts Supplemental Biologics License Application (sBLA) for
KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer |
|
|
|
|
|
Thermo Fisher Scientific Continues to Expand Leading Analytical
Instruments Offering for Customers in Applied Markets |
|
|
|
|
|
Agilent Technologies Makes $80 Million Investment in Emerging
Biotechnology Company Lasergen |
|
|
|
|
03/05/16 |
GSK presents new data on the long-term efficacy & safety of
Nucala® for the treatment of severe asthma with an eosinophilic phenotype |
|
|
|
|
03/04/16 |
Merck and the Mectizan Donation Program Donate $1 Million to the
END Fund for Efforts to Help Eliminate River Blindness in Africa |
|
|
|
|
03/01/16 |
Amgen Submits Supplemental Biologics License Application For
BLINCYTO® For Difficult-to-Treat Type of Pediatric Acute Lymphoblastic Leukemia |
|
|
|
|
|
U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based
Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir
Alafenamide) for the Treatment of HIV-1 Infection |
|
|
|
|
02/29/16 |
Roche provides update on two identical phase III studies of
lebrikizumab in people with severe asthma |
|
|
|
|
|
FDA approves Roche’s Gazyva (obinutuzumab) for certain people
with previously treated follicular lymphoma |
|
|
|
|
02/28/16 |
Genentech Provides Update on Two Identical Phase III Studies of
Lebrikizumab in People with Severe Asthma |
|
|
|
|
02/26/16 |
Bristol-Myers Squibb Receives Two Positive CHMP Opinions for
Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous
Non-Small Cell Lung Cancer and Renal Cell Carcinoma |
|
|
|
|
|
FDA approves new indication for Novartis drug Afinitor® for
progressive, nonfunctional GI and lung neuroendocrine tumors (NET) |
|
|
|
|
|
FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People
with Previously Treated Follicular Lymphoma |
|
|
|
|
|
Japanese MHLW Grants Orphan Drug Designation in Japan to Takeda's
Oral Proteasome Inhibitor Ixazomib for Patients with Relapsed/Refractory
Multiple Myeloma |
|
|
|
|
02/21/16 |
Amgen And UCB Announce Positive Top-Line Results From The Phase 3
Study Of Romosozumab In Postmenopausal Women With Osteoporosis |
|
|
|
|
02/19/16 |
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy
designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia
(AML) |
|
|
|
|
02/16/16 |
FDA Grants Breakthrough Therapy Designation for Genentech’s
Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis |
|
|
|
|
02/08/16 |
SCIEX Presents Revolutionary High Resolution Mass Spec System for
Routine Testing at ArabLab 2016 |
|
|
|
|
01/27/16 |
Agilent Technologies Wins Award for Innovation in Liquid
Chromatography Dual-Needle Technology Enhances Speed, Flexibility |
|
|
|
|
01/19/16 |
Lilly and Incyte Announce Submission of New Drug Application to
FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe
Rheumatoid Arthritis |
|
|
|
|
|
Agilent Technologies Extends Agreement with PerkinElmer on
Bioanalyzer Chips |
|
|
|
|
01/15/16 |
Merck Resolves Previously Disclosed Securities Class Action
Lawsuit Related to Vioxx |
|
|
|
|
|
Novartis receives two new FDA approvals for Cosentyx to treat
patients with ankylosing spondylitis and psoriatic arthritis in the US |
|
|
|
|
01/14/16 |
Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of
Imetelstat in Myelodysplastic Syndromes |
|
|
|
|
01/13/16 |
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to
Close Global Partnership on Filgotinib |
|
|
|
|
|
Pfizer Acquires Treerly and Its Family of Products from Sirio
Pharma |
|
|
|
|
01/12/16 |
Genentech:
FDA Grants Priority Review for Venetoclax New Drug Application |
|
|
|
|
|
Gilead Submits New Drug Application to U.S. Food and Drug
Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic
Hepatitis B |
|
|
|
|
|
SCIEX Announces Exclusive Co-Marketing Agreement with Pressure
BioSciences, Inc. to Improve Protein Quantitation in Complex Samples |
|
|
|
|
01/11/16 |
Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial
Collaboration |
|
|
|
|
01/08/16 |
Bayer halves the price of its contraceptive implant Jadelle® for
women in developing countries |
|
|
|
|
|
Roche presents
updated results for investigational cancer immunotherapy atezolizumab in
advanced bladder cancer |
|
|
|
|
|
Thermo Fisher Scientific to Acquire Affymetrix |
|
|
|
|
01/07/16 |
PROGNOSIS Study
Published in The New England Journal of Medicine Reveals Innovative Roche Blood
Test Can Be Used as a Predictive Tool for Preeclampsia |
|
|
|
|
01/06/16 |
GSK:
ViiV Healthcare to progress collaboration with Janssen to develop
the first long-acting, two drug injectable regimen for treatment of HIV-1
infection |
|
|
|
|
|
Gilead Terminates Phase 2 Study of Simtuzumab in Patients With
Idiopathic Pulmonary Fibrosis |
|
|
|
|
01/05/16 |
Gilead Announces Top-Line Results From Two Phase 3 Studies
Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B
Infection |
|
|
|
|
01/04/16 |
Depomed Announces Closing of Acquisition of U.S. Rights to
Cebranopadol From Grunenthal |
|
|
|
|
|
Gilead Announces U.S. FDA Priority Review Designation for
Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C
Infection |
|
|
|
|
12/21/15 |
Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop
and Commercialize Potential Cures for Serious Genetic Diseases |
|
|
|
|
12/18/15 |
Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV
Healthcare |
|
|
|
|
12/11/15 |
FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval
for People with a Specific Type of Lung Cancer |
|
|
|
|
11/08/15 |
Novartis presents new two year data for Cosentyx® showing no
progression in joint damage in 84% of psoriatic arthritis patients |
|
|
|
|
|
New two year data for Novartis' Cosentyx® show sustained response
and no progression in spinal damage as shown by x-ray in up to 80% of patients
with ankylosing spondylitis |
|
|
|
|
11/07/15 |
Detailed Results Demonstrate Baricitinib Superiority to
Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis |
|
|
|
|
|
GSK announces positive results from phase
III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in
patients with systemic lupus erythematosus |
|
|
|
|
11/05/15 |
Pfizer
Global Analysis Of Metastatic Breast Cancer Landscape Reveals
Gaps In Patient Care And Support |
|
|
|
|
|
European Medicines Agency Validates Bristol-Myers Squibb’s Type
II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced
Renal Cell Carcinoma |
|
|
|
|
|
Further refugee aid measure:
Bayer donates medicines for refugees in Turkey, Greece and
Austria |
|
|
|
|
|
Agilent Technologies Signs Instrument Control Exchange Agreement
with Thermo Fisher Scientific |
|
|
|
|
|
U.S. Food and Drug Administration Approves Gilead’s Single Tablet
Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir
Alafenamide) for Treatment of HIV-1 Infection |
|
|
|
|
11/04/15 |
Merck and Pfizer Announce Initiation of Phase III First-Line
Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung
Cancer |
|
|
|
|
|
GSK’s Nucala® (mepolizumab) receives approval from US FDA
First anti-IL5 treatment for adults and adolescents
with severe asthma with an eosinophilic phenotype |
|
|
|
|
|
Novartis nominating Elizabeth Doherty and Ton Buechner to the
Board of Directors |
|
|
|
|
11/03/15 |
Epacadostat in Combination with Pembrolizumab Demonstrates
Promising Clinical Activity in Multiple Advanced Cancers |
|
|
|
|
|
ISS and Glass Lewis Recommend Horizon Pharma Shareholders Vote
AGAINST the Issuance of Horizon Shares in Connection with Horizon's Attempted
Takeover of Depomed |
|
|
|
|
11/02/15 |
New Data Continue to Characterize the Safety and Efficacy of
XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis |
|
|
|
|
|
Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc |
|
|
|
|
|
Agilent Technologies Completes Acquisition of Seahorse
Bioscience, Industry Leader in Tools for Measuring Cell Metabolism |
|
|
|
|
|
Bruker eDispatch, Issue 63, November 2015
Get the latest news for Separations & Mass Spec with Bruker's
eDispatch monthly Newsletter |
|
|
|
|
10/28/15 |
Bristol-Myers Squibb Receives Approval from the U.S. Food and
Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully
Resected Stage III Melanoma |
|
|
|
|
|
Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix
Galien USA 2015 Award for Best Biotechnology Product |
|
|
|
|
10/27/15 |
Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3
ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in
Previously Untreated Advanced Hodgkin Lymphoma (HL) |
|
|
|
|
10/23/15 |
Complete Phase 2a Study of HIV-1 Investigational Maturation
Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus
Differently Than Existing Treatments |
|
|
|
|
10/14/15 |
Baricitinib Demonstrates Superiority to Adalimumab in Improving
Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study |
|
|
|
|
10/09/15 |
Dako, an Agilent Technologies Company, Announces FDA Approval of
New Test for Lung Cancer Patients |
|
|
|
|
10/08/15 |
Genentech’s Ocrelizumab First Investigational Medicine to Show
Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms
of Multiple Sclerosis |
|
|
|
|
10/07/15 |
Nektar Submits Investigational New Drug Application (IND) for
NKTR-214 To Treat Solid Tumor Malignancies |
|
|
|
|
10/06/15 |
Nektar Closes Direct Private Placement with TPG Special
Situations Partners of $250 Million of Senior Secured Notes Due in 2020 |
|
|
|
|
10/02/15 |
Bayer CropScience hosts Weed Resistance Global Symposium in Paris:
Knowledge exchange, collaboration and innovation are key to fighting global weed
resistance more
|
|
|
|
|
|
FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with
Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease
Progression On or After Platinum-Containing Chemotherapy |
|
|
|
|
10/01/15 |
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug
Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF
V600 Wild-Type Unresectable or Metastatic Melanoma |
|
|
|
|
|
Bayer CropScience hosts Horticulture Symposium in Mexico:
Joining hands for sustainability and innovation in horticulture |
|
|
|
|
9/30/15 |
Thermo Fisher Scientific Completes Acquisition of Alfa Aesar to
Significantly Expand Laboratory Chemicals Offering |
|
|
|
|
9/29/15 |
Shimadzu's Nexera MX Ultra Fast Multianalyte LCMS System Offers
Excellent Operational Efficiency and Up to Double the Previous Sample Processing
Capability |
|
|
|
|
9/28/15 |
Roche's ocrelizumab first investigational
medicine to show efficacy in people with primary progressive multiple sclerosis
in large Phase III study |
|
|
|
|
|
Bruker Introduces the rapifleX™ MALDI-TOF/TOF
at HUPO |
|
|
|
|
9/27/15 |
Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in
Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in
CheckMate -057 |
|
|
|
|
|
Genentech’s Ocrelizumab First Investigational Medicine to Show
Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase
III Study |
|
|
|
|
9/25/15 |
Amgen Receives CHMP Positive Opinions For Two New Treatment
Options For Patients With Blood Cancer In Europe
|
|
|
|
|
|
Opdivo (nivolumab) Demonstrates Superior Overall Survival in a
Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated
Advanced Renal Cell Carcinoma |
|
|
|
|
|
Bruker’s NMR FoodScreener™ Laboratory
Achieves ISO/IEC 17025 Accreditation |
|
|
|
|
9/24/15 |
SCIEX Announces Exclusive Reseller Agreement with Advaita
Bioinformatics |
|
|
|
|
|
Development of new wheat varieties in Saxony-Anhalt:
Bayer CropScience expands its European Center for Wheat Breeding
in Gatersleben |
|
|
|
|
|
GSK receives positive CHMP opinion in
Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of
patients with severe refractory eosinophilic asthma |
|
|
|
|
9/23/15 |
New Phase IIIb/IV data show switching to once-daily Triumeq®
maintains HIV viral suppression |
|
|
|
|
|
Agilent Technologies Announces Opening of Life Science Research
Center at Carleton University |
|
|
|
|
|
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating
a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL)
(GS-5816) for the Treatment of All Six Hepatitis C Genotypes |
|
|
|
|
9/16/15 |
Amgen To Acquire Privately-Held Dezima Pharma |
|
|
|
|
9/9/15 |
Gilead Prices $10 Billion of Senior Unsecured Notes
|
|
|
|
|
9/8/15 |
FDA Grants Genentech's Alectinib Priority Review for Specific
Type of ALK-Positive Lung Cancer |
|
|
Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. |
|
|
|
